Beovu® (brolucizumab-dbll)

Beovu (brolucizumab‑dbll) is covered only for FDA‑approved neovascular (wet) AMD, diabetic macular edema, and specified compendial off‑label neovascular ophthalmic conditions; other uses are excluded. Coverage requires documentation of the indicated diagnosis, administration by or under an ophthalmologist, adherence to indication‑specific dosing (AMD/other neovascular: 6 mg monthly for 3 doses then every 8–12 weeks; DME: 6 mg every ~6 weeks for 5 doses then every 8–12 weeks), and approvals are valid for 12 months.

"Neovascular (Wet) Age-related Macular Degeneration (AMD)"

Sign up to see full coverage criteria, indications, and limitations.